Top

Published in:

01-12-2015 | AUTOIMMUNITY/IMMUNOREGULATION/INFLAMMATION

Immunological function of Blimp-1 in dendritic cells and relevance to autoimmune diseases

Author: Sun Jung Kim

Published in: Immunologic Research | Issue 1-3/2015

Abstract

Previous studies have identified the immunological functions of transcription factor B lymphocyte-induced maturation protein-1 (Blimp-1) in various adaptive immune cell types such as T and B lymphocytes. More recently, it has been shown that Blimp-1 extends its functional roles to dendritic cells (DCs) and macrophages, two cell types belonging to the innate immune system. The protein acts as a direct and indirect regulator of target genes by recruiting chromatin modification factors and by regulating microRNA expression, respectively. In DCs, Blimp-1 has been identified as one of the components involved in antigen presentation. Genome-wide association studies identified polymorphisms associated with multiple autoimmune diseases such as system lupus erythematosus, rheumatoid arthritis, and inflammatory bowel disease in PRDM1, the gene encoding Blimp-1 protein. In this review, we will discuss the immune regulatory functions of Blimp-1 in DCs with a main focus on the tolerogenic mechanisms of Blimp-1 required to protect against the development of autoimmune diseases.

Keller AD, Maniatis T. Identification and characterization of a novel repressor of beta-interferon gene expression. Genes Dev. 1991;5(5):868–79.CrossRefPubMed

Turner CA Jr, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell. 1994;77(2):297–306.CrossRefPubMed

Huang S. Blimp-1 is the murine homolog of the human transcriptional repressor PRDI-BF1. Cell. 1994;78(1):9.CrossRefPubMed

Keller AD, Maniatis T. Only two of the five zinc fingers of the eukaryotic transcriptional repressor PRDI-BF1 are required for sequence-specific DNA binding. Mol Cell Biol. 1992;12(5):1940–9.PubMedCentralCrossRefPubMed

Kuo TC, Calame KL. B lymphocyte-induced maturation protein (Blimp)-1, IFN regulatory factor (IRF)-1, and IRF-2 can bind to the same regulatory sites. J Immunol. 2004;173(9):5556–63.CrossRefPubMed

Dillon SC, Zhang X, Trievel RC, Cheng X. The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol. 2005;6(8):227. doi:10.1186/gb-2005-6-8-227.PubMedCentralCrossRefPubMed

Gyory I, Wu J, Fejer G, Seto E, Wright KL. PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat Immunol. 2004;5(3):299–308. doi:10.1038/ni1046.CrossRefPubMed

Ancelin K, Lange UC, Hajkova P, Schneider R, Bannister AJ, Kouzarides T, et al. Blimp1 associates with Prmt5 and directs histone arginine methylation in mouse germ cells. Nat Cell Biol. 2006;8(6):623–30. doi:10.1038/ncb1413.CrossRefPubMed

Shin HM, Kapoor VN, Guan T, Kaech SM, Welsh RM, Berg LJ. Epigenetic modifications induced by Blimp-1 Regulate CD8(+) T cell memory progression during acute virus infection. Immunity. 2013;39(4):661–75. doi:10.1016/j.immuni.2013.08.032.CrossRefPubMed

10.

Savitsky D, Calame K. B-1 B lymphocytes require Blimp-1 for immunoglobulin secretion. J Exp Med. 2006;203(10):2305–14. doi:10.1084/jem.20060411.PubMedCentralCrossRefPubMed

11.

Schliephake DE, Schimpl A. Blimp-1 overcomes the block in IgM secretion in lipopolysaccharide/anti-mu F(ab’)2-co-stimulated B lymphocytes. Eur J Immunol. 1996;26(1):268–71. doi:10.1002/eji.1830260142.CrossRefPubMed

12.

Genestier L, Taillardet M, Mondiere P, Gheit H, Bella C, Defrance T. TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. J Immunol. 2007;178(12):7779–86.CrossRefPubMed

13.

Capolunghi F, Cascioli S, Giorda E, Rosado MM, Plebani A, Auriti C, et al. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol. 2008;180(2):800–8.CrossRefPubMed

14.

Ghamlouch H, Ouled-Haddou H, Guyart A, Regnier A, Trudel S, Claisse JF, et al. TLR9 ligand (CpG oligodeoxynucleotide) induces CLL B-cells to differentiate into CD20(+) antibody-secreting cells. Front Immunol. 2014;5:292. doi:10.3389/fimmu.2014.00292.PubMedCentralCrossRefPubMed

15.

Li FJ, Schreeder DM, Li R, Wu J, Davis RS. FCRL3 promotes TLR9-induced B-cell activation and suppresses plasma cell differentiation. Eur J Immunol. 2013;43(11):2980–92. doi:10.1002/eji.201243068.CrossRefPubMed

16.

Gong D, Malek TR. Cytokine-dependent Blimp-1 expression in activated T cells inhibits IL-2 production. J Immunol. 2007;178(1):242–52.CrossRefPubMed

17.

Chen-Kiang S. Regulation of terminal differentiation of human B-cells by IL-6. Curr Top Microbiol Immunol. 1995;194:189–98.PubMed

18.

Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, Qi CF, et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol. 2004;173(9):5361–71.CrossRefPubMed

19.

Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA. 1992;89(5):1890–3.PubMedCentralCrossRefPubMed

20.

Vasanwala FH, Kusam S, Toney LM, Dent AL. Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene. J Immunol. 2002;169(4):1922–9.CrossRefPubMed

21.

Ohkubo Y, Arima M, Arguni E, Okada S, Yamashita K, Asari S, et al. A role for c-fos/activator protein 1 in B lymphocyte terminal differentiation. J Immunol. 2005;174(12):7703–10.CrossRefPubMed

22.

Mittrucker HW, Matsuyama T, Grossman A, Kundig TM, Potter J, Shahinian A, et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science. 1997;275(5299):540–3.CrossRefPubMed

23.

Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity. 2006;25(2):225–36. doi:10.1016/j.immuni.2006.07.009.CrossRefPubMed

24.

Deng Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol. 2010;6(12):683–92. doi:10.1038/nrrheum.2010.176.PubMedCentralCrossRefPubMed

25.

Barcellos LF, May SL, Ramsay PP, Quach HL, Lane JA, Nititham J, et al. High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions. PLoS Genet. 2009;5(10):e1000696. doi:10.1371/journal.pgen.1000696.PubMedCentralCrossRefPubMed

26.

Rioux JD, Goyette P, Vyse TJ, Hammarstrom L, Fernando MM, Green T, et al. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci USA. 2009;106(44):18680–5. doi:10.1073/pnas.0909307106.PubMedCentralCrossRefPubMed

27.

Kawasaki A, Furukawa H, Kondo Y, Ito S, Hayashi T, Kusaoi M, et al. TLR7 single-nucleotide polymorphisms in the 3’ untranslated region and intron 2 independently contribute to systemic lupus erythematosus in Japanese women: a case-control association study. Arthritis Res Ther. 2011;13(2):R41. doi:10.1186/ar3277.PubMedCentralCrossRefPubMed

28.

Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008;58(8):2481–7. doi:10.1002/art.23613.PubMedCentralCrossRefPubMed

29.

Abelson AK, Delgado-Vega AM, Kozyrev SV, Sanchez E, Velazquez-Cruz R, Eriksson N, et al. STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis. 2009;68(11):1746–53. doi:10.1136/ard.2008.097642.CrossRefPubMed

30.

Jacob CO, Zhu J, Armstrong DL, Yan M, Han J, Zhou XJ, et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci USA. 2009;106(15):6256–61. doi:10.1073/pnas.0901181106.PubMedCentralCrossRefPubMed

31.

Adrianto I, Wen F, Templeton A, Wiley G, King JB, Lessard CJ, et al. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet. 2011;43(3):253–8. doi:10.1038/ng.766.PubMedCentralCrossRefPubMed

32.

Wu H, Cantor RM, Graham DS, Lingren CM, Farwell L, Jager PL, et al. Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease. Arthritis Rheum. 2005;52(8):2396–402. doi:10.1002/art.21223.CrossRefPubMed

33.

Liu JL, Zhang FY, Liang YH, Xiao FL, Zhang SQ, Cheng YL, et al. Association between the PD1.3A/G polymorphism of the PDCD1 gene and systemic lupus erythematosus in European populations: a meta-analysis. J Eur Acad Dermatol Venereol. 2009;23(4):425–32. doi:10.1111/j.1468-3083.2009.03087.x.CrossRefPubMed

34.

Lu R, Vidal GS, Kelly JA, Delgado-Vega AM, Howard XK, Macwana SR, et al. Genetic associations of LYN with systemic lupus erythematosus. Genes Immun. 2009;10(5):397–403. doi:10.1038/gene.2009.19.PubMedCentralCrossRefPubMed

35.

Simpfendorfer KR, Olsson LM, Manjarrez Orduno N, Khalili H, Simeone AM, Katz MS, et al. The autoimmunity-associated BLK haplotype exhibits cis-regulatory effects on mRNA and protein expression that are prominently observed in B cells early in development. Hum Mol Genet. 2012;21(17):3918–25. doi:10.1093/hmg/dds220.PubMedCentralCrossRefPubMed

36.

Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med. 2008;358(9):900–9. doi:10.1056/NEJMoa0707865.CrossRefPubMed

37.

Radanova M, Vasilev V, Dimitrov T, Deliyska B, Ikonomov V, Ivanova D. Association of rs172378 C1q gene cluster polymorphism with lupus nephritis in Bulgarian patients. Lupus. 2015;24(3):280–9. doi:10.1177/0961203314555173.CrossRefPubMed

38.

Karassa FB, Trikalinos TA, Ioannidis JP. Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum. 2002;46(6):1563–71. doi:10.1002/art.10306.CrossRefPubMed

39.

Jonsen A, Gunnarsson I, Gullstrand B, Svenungsson E, Bengtsson AA, Nived O, et al. Association between SLE nephritis and polymorphic variants of the CRP and FcgammaRIIIa genes. Rheumatology (Oxford). 2007;46(9):1417–21. doi:10.1093/rheumatology/kem167.CrossRef

40.

Li X, Wu J, Carter RH, Edberg JC, Su K, Cooper GS, et al. A novel polymorphism in the Fcgamma receptor IIB (CD32B) transmembrane region alters receptor signaling. Arthritis Rheum. 2003;48(11):3242–52. doi:10.1002/art.11313.CrossRefPubMed

41.

Chen JY, Wang CM, Ma CC, Luo SF, Edberg JC, Kimberly RP, et al. Association of a transmembrane polymorphism of Fcgamma receptor IIb (FCGR2B) with systemic lupus erythematosus in Taiwanese patients. Arthritis Rheum. 2006;54(12):3908–17. doi:10.1002/art.22220.CrossRefPubMed

42.

Fan Y, Li LH, Pan HF, Tao JH, Sun ZQ, Ye DQ. Association of ITGAM polymorphism with systemic lupus erythematosus: a meta-analysis. J Eur Acad Dermatol Venereol. 2011;25(3):271–5. doi:10.1111/j.1468-3083.2010.03776.x.CrossRefPubMed

43.

Toller-Kawahisa JE, Vigato-Ferreira IC, Pancoto JA, Mendes-Junior CT, Martinez EZ, Palomino GM, et al. The variant of CD11b, rs1143679 within ITGAM, is associated with systemic lupus erythematosus and clinical manifestations in Brazilian patients. Hum Immunol. 2014;75(2):119–23. doi:10.1016/j.humimm.2013.11.013.CrossRefPubMed

44.

Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X, et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet. 2009;41(11):1228–33. doi:10.1038/ng.468.PubMedCentralCrossRefPubMed

45.

Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, Hu Z, et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet. 2009;41(11):1234–7. doi:10.1038/ng.472.CrossRefPubMed

46.

Zhou XJ, Lu XL, Lv JC, Yang HZ, Qin LX, Zhao MH, et al. Genetic association of PRDM1-ATG5 intergenic region and autophagy with systemic lupus erythematosus in a Chinese population. Ann Rheum Dis. 2011;70(7):1330–7. doi:10.1136/ard.2010.140111.CrossRefPubMed

47.

Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42(12):1118–25. doi:10.1038/ng.717.PubMedCentralCrossRefPubMed

48.

Martins G, Calame K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol. 2008;26:133–69. doi:10.1146/annurev.immunol.26.021607.090241.CrossRefPubMed

49.

Chang DH, Angelin-Duclos C, Calame K. BLIMP-1: trigger for differentiation of myeloid lineage. Nat Immunol. 2000;1(2):169–76. doi:10.1038/77861.CrossRefPubMed

50.

Iwakoshi NN, Pypaert M, Glimcher LH. The transcription factor XBP-1 is essential for the development and survival of dendritic cells. J Exp Med. 2007;204(10):2267–75. doi:10.1084/jem.20070525.PubMedCentralCrossRefPubMed

51.

Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee AH, Qian SB, Zhao H, et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity. 2004;21(1):81–93. doi:10.1016/j.immuni.2004.06.010.CrossRefPubMed

52.

Kim SJ, Zou YR, Goldstein J, Reizis B, Diamond B. Tolerogenic function of Blimp-1 in dendritic cells. J Exp Med. 2011;208(11):2193–9. doi:10.1084/jem.20110658.PubMedCentralCrossRefPubMed

53.

Nurieva RI, Chung Y, Hwang D, Yang XO, Kang HS, Ma L, et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity. 2008;29(1):138–49. doi:10.1016/j.immuni.2008.05.009.PubMedCentralCrossRefPubMed

54.

Poholek AC, Hansen K, Hernandez SG, Eto D, Chandele A, Weinstein JS, et al. In vivo regulation of Bcl6 and T follicular helper cell development. J Immunol. 2010;185(1):313–26. doi:10.4049/jimmunol.0904023.PubMedCentralCrossRefPubMed

55.

Choi YS, Eto D, Yang JA, Lao C, Crotty S. Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation. J Immunol. 2013;190(7):3049–53. doi:10.4049/jimmunol.1203032.PubMedCentralCrossRefPubMed

56.

Kim SJ, Gregersen PK, Diamond B. Regulation of dendritic cell activation by microRNA let-7c and BLIMP1. J Clin Invest. 2013;123(2):823–33. doi:10.1172/JCI64712.PubMedCentralPubMed

57.

Salehi S, Bankoti R, Benevides L, Willen J, Couse M, Silva JS, et al. B lymphocyte-induced maturation protein-1 contributes to intestinal mucosa homeostasis by limiting the number of IL-17-producing CD4+ T cells. J Immunol. 2012;189(12):5682–93. doi:10.4049/jimmunol.1201966.PubMedCentralCrossRefPubMed

58.

Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119–24. doi:10.1038/nature11582.PubMedCentralCrossRefPubMed

59.

Watchmaker PB, Lahl K, Lee M, Baumjohann D, Morton J, Kim SJ, et al. Comparative transcriptional and functional profiling defines conserved programs of intestinal DC differentiation in humans and mice. Nat Immunol. 2014;15(1):98–108. doi:10.1038/ni.2768.PubMedCentralCrossRefPubMed

60.

Kim SJ, Goldstein J, Dorso K, Merad M, Mayer L, Crawford JM, et al. Expression of Blimp-1 in dendritic cells modulates the innate inflammatory response in dextran sodium sulfate-induced colitis. Mol Med. 2014;20:707–19. doi:10.2119/molmed.2014.00231.PubMedCentralCrossRef

61.

Bianchi V, Maconi G, Ardizzone S, Colombo E, Ferrara E, Russo A, et al. Association of NOD2/CARD15 mutations on Crohn’s disease phenotype in an Italian population. Eur J Gastroenterol Hepatol. 2007;19(3):217–23. doi:10.1097/01.meg.0000250590.84102.12.CrossRefPubMed

62.

Piskurich JF, Lin KI, Lin Y, Wang Y, Ting JP, Calame K. BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat Immunol. 2000;1(6):526–32. doi:10.1038/82788.CrossRefPubMed

63.

Smith MA, Wright G, Wu J, Tailor P, Ozato K, Chen X, et al. Positive regulatory domain I (PRDM1) and IRF8/PU.1 counter-regulate MHC class II transactivator (CIITA) expression during dendritic cell maturation. J Biol Chem. 2011;286(10):7893–904. doi:10.1074/jbc.M110.165431.PubMedCentralCrossRefPubMed

64.

VanderLugt B, Khan AA, Hackney JA, Agrawal S, Lesch J, Zhou M, et al. Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation. Nat Immunol. 2014;15(2):161–7. doi:10.1038/ni.2795.CrossRef

65.

Cretney E, Xin A, Shi W, Minnich M, Masson F, Miasari M, et al. The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells. Nat Immunol. 2011;12(4):304–11. doi:10.1038/ni.2006.CrossRefPubMed

66.

Vinuesa CG, Cook MC, Angelucci C, Athanasopoulos V, Rui L, Hill KM, et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature. 2005;435(7041):452–8. doi:10.1038/nature03555.CrossRefPubMed

67.

Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol. 2001;167(4):2361–9.CrossRefPubMed

68.

Ansel KM, McHeyzer-Williams LJ, Ngo VN, McHeyzer-Williams MG, Cyster JG. In vivo-activated CD4 T cells upregulate CXC chemokine receptor 5 and reprogram their response to lymphoid chemokines. J Exp Med. 1999;190(8):1123–34.PubMedCentralCrossRefPubMed

69.

Kitano M, Moriyama S, Ando Y, Hikida M, Mori Y, Kurosaki T, et al. Bcl6 protein expression shapes pre-germinal center B cell dynamics and follicular helper T cell heterogeneity. Immunity. 2011;34(6):961–72. doi:10.1016/j.immuni.2011.03.025.CrossRefPubMed

70.

Haynes NM, Allen CD, Lesley R, Ansel KM, Killeen N, Cyster JG. Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation. J Immunol. 2007;179(8):5099–108.CrossRefPubMed

71.

Schmitt N, Liu Y, Bentebibel SE, Munagala I, Bourdery L, Venuprasad K, et al. The cytokine TGF-beta co-opts signaling via STAT3–STAT4 to promote the differentiation of human TFH cells. Nat Immunol. 2014;15(9):856–65. doi:10.1038/ni.2947.PubMedCentralCrossRefPubMed

72.

Shi GP, Munger JS, Meara JP, Rich DH, Chapman HA. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. J Biol Chem. 1992;267(11):7258–62.PubMed

73.

Riese RJ, Wolf PR, Bromme D, Natkin LR, Villadangos JA, Ploegh HL, et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity. 1996;4(4):357–66.CrossRefPubMed

74.

Hsieh CS, deRoos P, Honey K, Beers C, Rudensky AY. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation. J Immunol. 2002;168(6):2618–25.CrossRefPubMed

75.

Fazilleau N, McHeyzer-Williams LJ, Rosen H, McHeyzer-Williams MG. The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding. Nat Immunol. 2009;10(4):375–84. doi:10.1038/ni.1704.PubMedCentralCrossRefPubMed

76.

Yang H, Kala M, Scott BG, Goluszko E, Chapman HA, Christadoss P. Cathepsin S is required for murine autoimmune myasthenia gravis pathogenesis. J Immunol. 2005;174(3):1729–37.CrossRefPubMed

77.

Nakagawa TY, Brissette WH, Lira PD, Griffiths RJ, Petrushova N, Stock J, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity. 1999;10(2):207–17.CrossRefPubMed

78.

Saegusa K, Ishimaru N, Yanagi K, Arakaki R, Ogawa K, Saito I, et al. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest. 2002;110(3):361–9. doi:10.1172/JCI14682.PubMedCentralCrossRefPubMed

79.

Rupanagudi KV, Kulkarni OP, Lichtnekert J, Darisipudi MN, Mulay SR, Schott B, et al. Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. Ann Rheum Dis. 2015;74(2):452–63. doi:10.1136/annrheumdis-2013-203717.CrossRefPubMed

Title: Immunological function of Blimp-1 in dendritic cells and relevance to autoimmune diseases
Author: Sun Jung Kim
Publication date: 01-12-2015
Publisher: Springer US
Published in: Immunologic Research / Issue 1-3/2015
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-015-8694-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Immunological function of Blimp-1 in dendritic cells and relevance to autoimmune diseases

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-3/2015

EGCG induces G-CSF expression and neutrophilia in experimental sepsis

Neural circuitry and immunity

A pilot study to determine the optimal timing of the Physician Global Assessment (PGA) in patients with systemic lupus erythematosus

Molecular studies of lupus nephritis kidneys

Poly(I:C) induces controlled release of IL-36γ from keratinocytes in the absence of cell death

The Genotype and Phenotype (GaP) registry: a living biobank for the analysis of quantitative traits